Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the publication of a peer-reviewed study in Biomedicines that demonstrates how its artificial intelligence-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma (HCC), the most common form of liver cancer. The study, published October 23, 2026, used Oncotelic's patented Partitioned Literature Aggregation (PLA) algorithm running on PDAOAI, combined with gene-expression and survival analyses, to pinpoint four genes: FKBP1A, EIF4E, RRAGC, and PPARGC1A. The signature's association with patient survival was independently validated in a Japanese HCC cohort of 203 patients, lending credibility to the findings.
The identification of this genetic signature matters because it could enable more precise patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus that Oncotelic is developing. By using the four-gene signature to select patients most likely to benefit, the company may improve the odds of success in later-stage testing, a critical consideration in oncology drug development where heterogeneous patient responses often complicate trial outcomes. The research approach was presented by Oncotelic Chief Business Officer Saran Saund during an October 22 keynote at the 22nd Drug Discovery Strategic Summit in California, highlighting the company's push to integrate AI into early-stage discovery.
The implications extend beyond this single study. Oncotelic plans to expand PDAOAI toward a target scale of approximately 100 billion biological vectors for genetic and protein research, suggesting a broader ambition to build a computational engine that can generate testable biological hypotheses at scale. Through its BIO REBOOT initiative, the company is also inviting researchers and development teams to submit projects for potential funding and support in validation, formulation, regulatory planning, and clinical development, subject to scientific review and available resources. This open call could position Oncotelic as a hub for collaborative oncology research, leveraging its AI capabilities to accelerate projects that might otherwise languish.
For investors, the publication in a peer-reviewed journal adds a layer of scientific validation that is often missing from corporate announcements. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. The full press release can be viewed at https://ibn.fm/ctJ4J. BioMedWire, a specialized communications platform focused on biotechnology and life sciences, distributes this content as part of its BioMedWire service, one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform offers InvestorWire wire solutions, editorial syndication to 5,000+ outlets, and corporate communications solutions tailored to reach investors and industry stakeholders. Oncotelic's focus on cancers with substantial unmet needs and rare pediatric indications, combined with its AI-driven discovery efforts, underscores a strategy that seeks to leverage computational tools to uncover biological insights that could translate into tangible therapies.
